GRCE logo

GRACE THERAPEUTICS INC

GRCENASDAQ
🏆 #4452 by market capEarnings Nov 12US Equity
$2.01▲ $0.14 (+7.49%)
🌅 Pre-market$2.00▼ 0.50%Regular close · extended-hours price shown
🔔
Track GRCE
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 7.5%
7d▲ 5.0%
14d▲ 3.3%
30d▼ 5.2%
ytd▼ 42.6%
1y▼ 36.8%
🏦Market Cap
$33M
Small Cap
📈Revenue Growth (YoY)
0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$1.88 – $2.01
52-Week Range
$1.67 – $5.18
Volume (shares)
164,507
Avg Volume (shares)
—
Shares Outstanding
16.3M
Next Earnings
2026-11-12

Fundamentals Snapshot

Annual Revenue
—
Last Q Revenue
—
P/E Ratio
-1.6
P/S Ratio
0.0x
EPS (TTM)
$-1.24
Dividend Yield
0.00%
Dilution (1yr)
+2.0%
GRCE logo

GRACE THERAPEUTICS INC

GRCE
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$11M▼ −53.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$9M▼ −40.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
17.3M▲ +2.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$14M▼ −$5M YoY
StockOtter · stockotter.space

About GRACE THERAPEUTICS INC

Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage. Its development pipeline further includes GTX-102, an oral mucosal betamethasone spray intended for the management of ataxia-telangiectasia, and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. Established in 2002, the enterprise previously operated under the name Acasti Pharma Inc., before officially adopting Grace Therapeutics, Inc. in October 2024. The company's main offices are located in Princeton, New Jersey.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100

Analyst Ratings

ⓘ
Consensus
Buy
8 analysts
Strong Buy2
Buy5
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

GlobeNewsWire·Sep 3

Grace Therapeutics to Participate in the H.C. Wainright 28th Annual Global Investment Conference

PRINCETON, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable form

GlobeNewsWire·Aug 13

Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update

PRINCETON, N.J., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formu

GlobeNewsWire·Aug 4

Grace Therapeutics Announces $10 Million Private Placement

Expected gross proceeds anticipated to extend the Company's cash runway to the end of calendar 2028 Expected gross proceeds anticipated to extend the Company's cash runway to the end of calendar 2028